Codex DNA Inc (DNAY) Peer Comparison
$1.91
$-0.09
(-4.50%)
As on 08-Mar-2023 09:30EDT
Market cap
$38 Mln
Revenue (TTM)
$15 Mln
P/E Ratio
--
P/B Ratio
0.7
Div. Yield
0 %
Edit
| Codex DNA Inc (DNAY) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Repligen (RGEN) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
38 | 12,753 | 12,153 | 10,906 | 9,948 |
Revenue ($ Mln) |
15 | 1,505 | 6,164 | 613 | 785 |
Net Profit ($ Mln) |
-52.83 | 160.59 | 625.00 | -188.05 | 41.54 |
Net Margin (%) |
-342.67 | 10.67 | 5.41 | -30.68 | 5.29 |
RoE (%) |
-- | 10.86 | 11.84 | -28.10 | 1.97 |
Price to Earnings |
-- | 79.35 | 19.89 | -- | 251.81 |
Price-To-Book |
0.65 | 8.41 | 2.37 | 16.38 | 4.86 |
Income Statement ($ Mln)
| Codex DNA Inc (DNAY) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
15.41 | 747.59 | 5,212.00 | 294.01 | 670.53 |
|
Cost of Revenue
|
11.01 | 272.21 | 1,514.00 | 66.63 | 279.28 |
|
Gross Profit
|
4.30 | 475.38 | 3,698.00 | 227.38 | 391.25 |
|
Operating Expenses
|
60.73 | 482.88 | 3,105.00 | 260.26 | 224.01 |
|
Operating Profit (EBIT)
|
-50.70 | -7.50 | 593.00 | -32.87 | 167.25 |
|
Other Income
|
0.01 | -3.94 | -- | 1.29 | -0.99 |
|
Profit before Tax
|
-52.81 | -10.50 | 586.00 | -49.27 | 153.54 |
|
Provision for Tax
|
0.02 | -13.13 | 62.00 | 0.33 | 25.25 |
|
Profit after Tax (Net Income)
|
-52.83 | 2.62 | 524.00 | -49.59 | 128.29 |
|
Minority Interest
|
0.00 | -3.71 | -- | -- | -- |
|
Consolidated Profit
|
-52.83 | 5.28 | 524.00 | -49.59 | 128.29 |
Liabilities ($ Mln)
| Codex DNA Inc (DNAY) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
-105.61 | 953.93 | 5,568.00 | 587.15 | 1,750.07 |
|
Minority Interest
|
0.00 | -3.71 | -- | -- | -- |
|
Non-Current Liabilities
|
22.03 | 167.13 | 3,221.00 | 478.32 | 233.03 |
|
Current Liabilities
|
12.81 | 123.20 | 2,131.00 | 63.36 | 375.26 |
|
Total Liabilities
|
116.26 | 1,244.25 | 10,920.00 | 1,128.83 | 2,358.35 |
Assets ($ Mln)
| Codex DNA Inc (DNAY) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
25.96 | 562.78 | 6,496.00 | 642.70 | 1,426.68 |
|
Current Assets
|
62.19 | 681.47 | 4,424.00 | 486.13 | 931.68 |
|
Total Assets
|
116.26 | 1,244.25 | 10,920.00 | 1,128.83 | 2,358.35 |
|
Total Debt*
|
21.38 | 173.55 | 3,339.00 | 383.39 | 366.05 |
|
Net Current Assets
|
49.38 | 558.28 | 2,293.00 | 422.77 | 556.42 |
Cashflow ($ Mln)
| Codex DNA Inc (DNAY) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-36.70 | 9.50 | 877.00 | 24.71 | 119.02 |
|
Cash Flow from Investing Activities
|
-15.04 | -21.74 | -691.00 | -58.23 | -221.17 |
|
Cash from Financing Activities
|
121.08 | 0.84 | -645.00 | 39.26 | 0.96 |
|
Net Cash Inflow / Outflow
|
69.34 | -11.40 | -- | 3.96 | -113.48 |
Ratios
Profitability Ratios
| Codex DNA Inc (DNAY) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-97.46 | 0.28 | 5.86 | -5.19 | 6.54 |
|
ROE (%)
|
-119.27 | 0.33 | 9.66 | -7.91 | 7.82 |
|
ROA (%)
|
-45.29 | 0.25 | 4.78 | -4.65 | 6.02 |
|
EBIT Margin (%)
|
-351.97 | -- | -- | -- | -- |
|
Net Margin (%)
|
-342.67 | 0.35 | 10.05 | -16.79 | 19.16 |
|
Cash Profit Margin (%)
|
0.00 | -- | -- | -- | -- |
Growth Ratios
| Codex DNA Inc (DNAY) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
55.58 | 0.33 | 0.14 | 0.31 | 0.83 |
|
EBIT Growth (%)
|
-75.78 | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
-64.84 | 113.62 | 16.96 | 58.79 | 114.08 |
|
EPS Growth (%)
|
-- | 1.14 | 0.17 | 0.60 | 1.04 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Codex DNA Inc (DNAY) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-- | 4,102.34 | 58.00 | -42.05 | 119.15 |
|
Price / Book Value
|
-- | 11.28 | 5.46 | 3.55 | 8.73 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
1.94 | 1,198.96 | 26.76 | -1,393.86 | 74.03 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Codex DNA Inc (DNAY) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
-0.18 | 0.18 | 0.60 | 0.65 | 0.21 |
|
Short term debt to equity ratio
|
-0.01 | 0.01 | 0.09 | 0.00 | 0.15 |
|
Current Ratio
|
4.86 | 5.53 | 2.08 | 7.67 | 2.48 |
|
Quick Ratio
|
4.68 | 3.39 | 1.21 | 7.31 | 1.99 |
|
Interest Coverage
|
-14.89 | -0.47 | 8.90 | -2.68 | 12.96 |
Operating Efficiency Ratios
| Codex DNA Inc (DNAY) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
36.75 | 17.92 | 18.63 | 11.37 | 17.51 |
|
Asset Turnover
|
0.13 | 0.72 | 0.48 | 0.28 | 0.31 |
|
Receivable days
|
85.28 | 60.72 | 65.94 | 43.17 | 51.42 |
|
Inventory Days
|
80.40 | 324.07 | 426.41 | 106.41 | 182.78 |
|
Payable days
|
99.92 | 18.47 | 233.29 | 32.08 | 34.71 |
|
Cash Conversion Cycle
|
65.76 | 366.31 | 259.06 | 117.49 | 199.49 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
